research Severe steroid-dependent idiopathic angioedema with response to rituximab
A woman with severe angioedema improved significantly after treatment with rituximab.
Search
for
Sort by
Research
690-720 / 1000+ results 
research The pathogenesis of alopecia areata
Alopecia areata is an autoimmune disease affecting hair follicles and may harm heart health.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata
Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
research Evaluation of serum zinc level in patients with newly diagnosed and resistant alopecia areata
Patients with alopecia areata have lower zinc levels, and zinc supplements might help.
research Pernicious anemia associated with autoimmune hemolytic anemia and alopecia areata
A 16-year-old boy had pernicious anemia, autoimmune hemolytic anemia, and later developed alopecia areata.
research Treatment Effects of Intradermal Botulinum Toxin Type A Injection on Alopecia Areata
Botulinum toxin type A injections are not effective for severe alopecia areata.
research Dupliumab therapy for alopecia areata: a case series and review of the literature
Dupilumab may help treat alopecia areata without needing high IgE levels.
research The impact of levothyroxine on thyroid autoimmunity and hypothalamic–pituitary–thyroid axis activity in men with autoimmune hypothyroidism and early-onset androgenetic alopecia
Levothyroxine is less effective in men with early-onset male-pattern baldness.
research The Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases?
Androgens may influence T cells, contributing to higher autoimmune liver disease risk in women.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research 081 Simvastatin reduces autoimmune alopecia through direct action on T lymphocytes
Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
research Evaluation of oxidative stress, 3-Nitrotyrosine, and HMGB-1 levels in patients with wet type Age-Related Macular Degeneration
wAMD patients have higher oxidative stress, suggesting antioxidant treatment may help.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis
Combining triamcinolone acetonide with immunotherapy can help regrow hair in some alopecia totalis patients.
research Pernicious anemia in a patient with Type 1 diabetes mellitus and alopecia areata universalis
Patients with Type 1 diabetes should be screened for pernicious anemia.
research 067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases
COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
research Localized Primary Cutaneous Nodular Amyloidosis in a Patient With Paraproteinemia
An elderly man with skin amyloidosis and abnormal blood proteins was monitored without finding widespread disease after 18 months.
research 413 DC-HIL+ myeloid-derived suppressor cells are elevated in the peripheral blood and lesional skin of cutaneous lupus patients
Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
research Assessment of miR-19b-3p, miR-182-5p, and miR-155-5p expression and its relationship with alopecia areata severity
miR-155-5p can help diagnose and track alopecia areata severity.
research Linear immunoglobulin A/immunoglobulin G bullous dermatosis associated with Vogt-Koyanagi-Harada disease
A man had two rare autoimmune diseases that might be connected.
research Serum 25-hydroxy vitamin D3 level in Egyptian patients with alopecia areata
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review
People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
research Gamma/delta T cells and human skin reactivity to heavy metals
Gamma/delta T cells help defend skin against heavy metals.
research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
research Alopecia Areata in the Elderly: A 10-Year Retrospective Study
Alopecia areata in elderly people is usually mild and responds well to treatment.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.